What is Roth Capital’s Forecast for ChromaDex Q4 Earnings?

ChromaDex Co. (NASDAQ:CDXC) – Stock analysts at Roth Capital lowered their Q4 2024 EPS estimates for shares of ChromaDex in a report issued on Tuesday, November 5th. Roth Capital analyst S. Mcgowan now forecasts that the company will post earnings per share of $0.00 for the quarter, down from their prior estimate of $0.01. The consensus estimate for ChromaDex’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for ChromaDex’s FY2025 earnings at $0.05 EPS and Q3 2026 earnings at $0.05 EPS.

CDXC has been the topic of a number of other reports. Roth Mkm raised their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday.

ChromaDex Stock Performance

NASDAQ:CDXC opened at $6.99 on Thursday. ChromaDex has a 52 week low of $1.32 and a 52 week high of $7.08. The firm has a market cap of $530.77 million, a price-to-earnings ratio of 699.00 and a beta of 1.88. The firm’s 50-day simple moving average is $3.70 and its 200 day simple moving average is $3.28.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The business had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. During the same period last year, the firm earned ($0.01) earnings per share.

Hedge Funds Weigh In On ChromaDex

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its stake in shares of ChromaDex by 8.4% in the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after purchasing an additional 32,400 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in shares of ChromaDex in the 2nd quarter valued at approximately $597,000. Bank of New York Mellon Corp boosted its stake in shares of ChromaDex by 170.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after purchasing an additional 119,915 shares in the last quarter. BSW Wealth Partners acquired a new stake in shares of ChromaDex in the 3rd quarter valued at approximately $324,000. Finally, OneDigital Investment Advisors LLC boosted its stake in shares of ChromaDex by 5.5% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock valued at $217,000 after purchasing an additional 3,097 shares in the last quarter. 15.41% of the stock is owned by institutional investors.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 9.64% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.